Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

Abstract

Congenital haemophilia A (HA) is caused by deficiency of coagulation factor VIII (FVIII) activity, leading to spontaneous or traumatic bleeding events. While FVIII replacement therapy can treat and prevent bleeds, approximately 30% of patients with severe HA develop inhibitor antibodies that render FVIII replacement therapy ineffective. The bypassing agents (BPAs), activated prothrombin complex concentrate (aPCC) and recombinant activated FVII, first approved in 1977 and 1996, respectively, act to generate thrombin independent of pathways that involve factors IX and VIII. Both may be used in patients with congenital haemophilia and inhibitors (PwHIs) for the treatment and prevention of acute bleeds and quickly became standard of care. However, individual patients respond differently to different agents. While both agents are approved for on-demand treatment and perioperative management for patients with congenital haemophilia with inhibitors, aPCC is currently the only BPA approved worldwide for prophylaxis in PwHI. Non-factor therapies (NFTs) have a mechanism of action distinct from BPAs and have reported higher efficacy rates as prophylactic regimens. Nonetheless, treatment challenges remain with NFTs, particularly regarding the potential for synergistic action on thrombin generation with concomitant use of other haemostatic agents, such as BPAs, for the treatment of breakthrough bleeds and in perioperative management. Concomitant use of NFTs with other haemostatic agents could increase the risk of adverse events such as thromboembolic events or thrombotic microangiopathy. This review focuses on the origins, development and on-going role of aPCC in the evolving treatment landscape in the management of PwHI.

Keywords

congenital haemophilia - inhibitors - bypassing agents - FEIBA - aPCC

Authors' Contributions

All authors jointly conceived the idea for the review. All authors contributed to writing of the manuscript, and all authors critically reviewed the manuscript at each stage of development.

Publikationsverlauf

Eingereicht: 12. Februar 2020

Angenommen: 16. April 2020

Artikel online veröffentlicht:
27. Juli 2020

• References

• 1 Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002; 55 (02) 127-144
• 2 Soucie JM, Cianfrini C, Janco RL. et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004; 103 (07) 2467-2473
• 3 Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999; 5 (03) 203-206
• 4 Collins PW, Chalmers E, Hart DP. et al; UK Haemophilia Centre Doctors Organization. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160 (02) 153-170
• 5 Rocino A, Coppola A, Franchini M. et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (04) 575-598
• 6 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
• 7 Valentino LA, Kempton CL, Kruse-Jarres R, Mathew P, Meeks SL, Reiss UM. ; International Immune Tolerance Induction Study Investigators. US guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia 2015; 21 (05) 559-567
• 8 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
• 9 Usuba K, Price VE, Blanchette V. et al. Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries. Res Pract Thromb Haemost 2019; 3 (03) 397-404
• 10 Björkman S. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia 2013; 19 (05) 753-757
• 11 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65 (10) 989-998
• 12 Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 2019; 133 (05) 399-406
• 13 Ehrenforth S, Kreuz W, Scharrer I. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339 (8793): 594-598
• 14 Carcao M, Goudemand J. Inhibitors in hemophilia: a primer. 5th ed. Montreal World Federation of Hemophilia 2018. Accessed January 2, 2020 at: http://www1.wfh.org/publication/files/pdf-1122.pdf
• 15 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15 (05) 1027-1031
• 16 Ewenstein BM, Takemoto C, Warrier I. et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89 (03) 1115-1116
• 17 Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16 (102) 66-70
• 18 Astermark J, Altisent C, Batorova A. et al; European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010; 16 (05) 747-766
• 19 Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. SeminThrombHemost 2013; 39 (07) 740-751
• 20 Kempton CL, White II GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009; 113 (01) 11-17
• 21 Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J Clin Med 2017; 6 (04) E46
• 22 Eckhardt CL, Loomans JI, van Velzen AS. et al; INSIGHT Study Group. Inhibitor development and mortality in non-severe hemophilia A. J ThrombHaemost 2015; 13 (07) 1217-1225
• 23 Walsh CE, Soucie JM, Miller CH. United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015; 90 (05) 400-405
• 24 National Hemophilia Foundation. Recommendation on the use and management of emicizumabKXWH (Hemlibra(r)) for hemophilia A with and without inhibitors. Published 2020. Accessed May 12, 2020 at: https://www.hemophilia.org/sites/default/files/document/files/258_emicizumab.pdf
• 25 Carcao M, Escuriola-Ettingshausen C, Santagostino E. et al; Future of Immunotolerance Treatment Group. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019; 25 (04) 676-684
• 26 Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood 2014; 124 (23) 3365-3372
• 27 Shire Pharmaceuticals Limited. FEIBA summary of product characteristics. Published 2019. Updated January 24, 2019. Accessed January 2, 2020 at: https://www.medicines.org.uk/emc/product/9192/smpc
• 28 Négrier C, Voisin S, Baghaei F. et al; FEIBA PASS Study group. Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis 2016; 27 (05) 551-556
• 29 Novo Nordisk Limited. NovoSeven 1 mg (50KIU) powder and solvent for solution for injection: Summary of Product Characteristics. Published 2018. Accessed January 2, 2020 at: https://www.medicines.org.uk/emc/product/6360/smpc#DOCREVISION
• 30 Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2015; (12) CD004449
• 31 Astermark J, Donfield SM, DiMichele DM. et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109 (02) 546-551
• 32 Breen Jr FAJ, Tullis JL. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA 1969; 208 (10) 1848-1852
• 33 DeWitt RT, Feinstein DI. Prothrombin complex concentrate. Arch Intern Med 1977; 137 (09) 1211-1213
• 34 Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291 (04) 164-167
• 35 Sultan Y, Brouet JC, Debre P. Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate. N Engl J Med 1974; 291 (20) 1087
• 36 Kelly P, Penner JA. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA 1976; 236 (18) 2061-2064
• 37 Prowse CV. Activated prothrombin complex concentrates: approaches to their preparation. Thromb Res 1982; 25 (03) 213-218
• 38 Turecek PL, Váradi K, Schwarz HP. Update on the mechanism of action and future of activated prothrombin complex concentrates. CurrHematol Rep 2004; 3 (05) 331-337
• 39 Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 2006; 12 (S5): 4-13
• 40 Shire. FEIBA (anti-inhibitor coagulant complex) for intravenous use, lyophilized powder for solution [Prescribing Information]. Published January 1, 2019. Accessed January 2, 2020 at: https://www.shirecontent.com/PI/PDFs/FEIBA_USA_ENG.pdf
• 41 Varadi K, Tangada S, Loeschberger M. et al. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. Haemophilia 2016; 22 (04) 615-624
• 42 Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10 (Suppl. 02) 3-9
• 43 Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61 (01) 36-40
• 44 Leissinger C, Gringeri A, Antmen B. et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365 (18) 1684-1692
• 45 Zülfikar B, Aydogan G, Salcioglu Z. et al; FEIBA Investigators Team. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey. Haemophilia 2012; 18 (03) 383-391
• 46 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138 (03) 305-315
• 47 Négrier C, Lienhart A, Numerof R. et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia 2013; 19 (03) e143-e150
• 48 Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12 (04) 352-362
• 49 Antunes SV, Tangada S, Stasyshyn O. et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20 (01) 65-72
• 50 Ewing N, Escuriola-Ettingshausen C, Kreuz W. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia 2015; 21 (03) 358-364
• 51 Nakar C, Manco-Johnson MJ, Lail A. et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia 2015; 21 (03) 365-373
• 52 Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol’: predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (01) (Suppl. 01) 49-54
• 53 Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2 (8044): 933
• 54 Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors--twenty years' ‘bonn protocol’. Vox Sang 1996; 70 (Suppl. 01) 30-35
• 55 Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. ProgClinBiol Res 1984; 150: 181-195
• 56 Zeitler H, Ulrich-Merzenich G, Hess L. et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005; 105 (06) 2287-2293
• 57 Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv 2017; 1 (26) 2637-2642
• 58 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (Suppl. 02) 10-16
• 59 duTreil S. Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med 2014; 5: 115-122
• 60 Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J ThrombHaemost 2009; 7 (09) 1446-1456
• 61 Kim YC, Zhang AH, Su Y. et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 2015; 125 (07) 1107-1115
• 62 Giangrande PLF, Hermans C, O'Mahony B. et al; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis 2018; 13 (01) 66
• 63 Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. ThrombHaemost 1997; 77 (06) 1113-1119
• 64 Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010; 16 (01) 90-100
• 65 Zanon E, Pasca S, Santoro C. et al. Activated prothrombin complex concentrate (FEIBA^®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry. Br J Haematol 2019; 184 (05) 853-855
• 66 Coppola A, Margaglione M, Santagostino E. et al; AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J ThrombHaemost 2009; 7 (11) 1809-1815
• 67 DiMichele DM, Kroner BL. North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. ThrombHaemost 2002; 87 (01) 52-57
• 68 Lenk H. ITT Study Group. The German Registry of immune tolerance treatment in hemophilia--1999 update. Haematologica 2000; 85 (10, Suppl): 45-47
• 69 Mariani G, Kroner B. Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86 (11) 1186-1193
• 70 Shapiro AD, Hedner U. Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. Ther Adv Drug Saf 2011; 2 (05) 213-225
• 71 Sørensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 (Suppl. 01) 1-6
• 72 Váradi K, Négrier C, Berntorp E. et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J ThrombHaemost 2003; 1 (11) 2374-2380
• 73 Windyga J, Holme P, Hermans C. et al. Real world clinical management of patients with hemophilia and inhibitors: effectiveness and safety of aPCC in patients with >18 months' follow-up in the FEIBA Global Outcome study (FEIBA GO). Blood 2019; 134 (S1): 2418
• 74 Ali TMCR, Wanek K, Cano V. Tolerability/safety of FEIBA reconstituted in regular or 50% reduced volume and faster infusion rates: rationale and study design in patients with hemophilia A or B with inhibitors. Haemophilia 2018; 24 (S1): 119
• 75 Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15 (01) 3-10
• 76 Genentech Inc. Hemlibra (emicizumab-kxwh) injection for subcutaneous use [Prescribing Information]. Published November 2017. Accessed January 2, 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf
• 77 Mahlangu J, Oldenburg J, Paz-Priel I. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
• 78 Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood 2018; 132 (01) 23-30
• 79 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
• 80 Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv 2019; 3 (11) 1722-1724
• 81 Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peyvandi F. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica 2019; 104 (08) e380-e382
• 82 Zimowski K, Batsuli GM, Reding MT. et al. Maintaining perioperative hemostasis in patients with severe hemophilia A and inhibitors receiving emicizumab prophylaxis. Blood 2018; 132: 635
• 83 Kruse-Jarres R, Callaghan MU, Croteau SE. et al. Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood 2017; 130: 89
• 84 Brophy DF, Martin EJ, Kuhn J. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors. Haemophilia 2019; 25 (02) e121-e123
• 85 Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Négrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103 (04) e181-e183
• 86 Dargaud Y, Lienhart A, Négrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116 (25) 5734-5737
• 87 van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009; 31 (02) 189-198
• 88 Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA. et al. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors. Haemophilia 2014; 20 (01) e7-e14
• 89 Turecek PL, Váradi K, Keil B. et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. PathophysiolHaemostThromb 2003; 33 (01) 16-22
• 90 Jiménez-Yuste V, Klamroth R, Castaman G. et al. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results. Res Pract Thromb Haemost 2019; 3 (S1): 116-117
• 91 Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost 2018; 16: 1580-1591
• 92 Oldenburg J, Levy GG. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (22) 2194-2195
• 93 Tiede A. Thromboembolic risks of non-factor replacement therapies in hemophilia. Hamostaseologie 2017; 37 (04) 307-310
• 94 Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12 (04) 352-362
• 95 Mahlangu J, Oldenburg J, Callaghan MU. et al. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia 2018; 24 (06) 921-929
• 96 Aledort LM, Ewenstein BM. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017; 377 (22) 2193
• 97 Genentech. Hemlibra. Serious Thrombotic Events. Published 2020. Accessed May 12, 2020 at: https://www.emicizumabinfo.com/content/dam/gene/emicizumabinfo/hcp/pdfs/serious_thrombotic_events.pdf
• 98 Rangarajan SGP, Mant T, Creagh MD. et al. Management of bleed events in the phase I study of fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia in patients with and without inhibitors. Haemophilia 2017; 23 (S2): 10
• 99 Fernandez-Bello I, Alvarez-Roman M, Martin-Salces M. et al. Thromboelastography may be useful for tailoring treatment of breakthrough bleeds in patients on prophylaxis with Concizumab. Haemophilia 2019; 25 (S1): 107-108
• 100 Augustsson C, Kjelgaard-Hansen M, Lind V, Hilden I. In vitro activity of concizumab in combination with activated prothrombin complex concentrate or rFVIIa as studied by thromboelastography and thrombin generation. Haemophilia 2018; 24 (S5): 43
• 101 Lauritzen B, Olling J, Abel KL. et al. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. J Thromb Haemost 2019; 17 (03) 460-469
• 102 Shiller EPV, Svirin P, Vdovin V. et al. Long-term prophylaxis with activated recombinant FVII in children with hemophilia A and inhibitor, receiving treatment with ITI protocol. Blood 2016; 128: 4980
• 103 Andreeva TA, Konstantinova VN. Adverse reactions using biosimilar of rFVIIa Coagil VII. 18th International Meeting Danubian League against Thrombosis and Haemorrhagic Disorders, Sarajevo, May 14–16, 2015. Published 2015. Accessed January 2, 2020 at: https://bib.irb.hr/datoteka/819844.DLTH-Abstract-Book-Sarajevo-2015.pdf
• 104 Faranoush M, Abolghasemi H, Mahboudi F. et al. A comparison of efficacy between recombinant activated factor VII (Aryoseven) and novoseven in patients with hereditary FVIII deficiency with inhibitor. Clin Appl Thromb Hemost 2016; 22 (02) 184-190
• 105 Shinkoda Y, Shirahata A, Fukutake K. et al. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia 2017; 23 (01) 59-66
• 106 Catalyst Biosciences. Factor VIIa marzeptacog alfa (activated). Published 2019. Accessed January 2, 2020 at: https://www.globenewswire.com/news-release/2018/09/04/1564830/0/en/Catalyst-Biosciences-Announces-Publication-of-Marzeptacog-Alfa-Activated-Phase-1-Data-in-The-Journal-of-Thrombosis-and-Haemostasis.html
• 107 Mahlangu J, Lamas JL, Morales JC. et al. A phase 1b/2 study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF-06741086, an anti-TFPI monoclonal antibody, in patients with severe hemophilia A or B. Res PractThrombHaemost 2019; 3 (S1): 85-86
• 108 Gruppo RA, Malan D, Kapocsi J. et al; Marzeptacog alfa (activated) Study Group Investigators. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. J ThrombHaemost 2018; 16 (10) 1984-1993
• 109 Mahlangu J, Levy H, Khacchatryan H. et al. Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacoga Lfa (activated) in hemophilia A or B with inhibitors: efficacy, safety and pharmacokinetics. Res Pract Thromb Haemost 2019; 3 (S1): 86-87
• 110 PR Newswire. HEMA Biologics, LLC announced today the acceptance by U.S. Food and Drug Administration of the submitted biologic license application for coagulation factor VIIa recombinant (eptacog beta activated). Published 2017. Accessed January 2, 2020 at: https://www.prnewswire.com/news-releases/hema-biologics-llc-announced-today-the-acceptance-by-us-food-and-drug-administration-of-the-submitted-biologic-license-application-for-coagulation-factor-viia-recombinant-eptacog-beta-activated-300387578.html
• 111 Hema Biologics. Pipeline. Published 2019. Accessed January 2, 2020 at: https://hemabio.com/pipeline/
• 112 George LA. Hemophilia gene therapy comes of age. Hematology (Am Soc Hematol Educ Program) 2017; 2017 (01) 587-594
• 113 Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy: paving new roads in the treatment of hemophilia. Semin Thromb Hemost 2019; 45 (07) 743-750
• 114 UniQure. Gene therapy: hemophilia. Published 2019. Accessed January 2, 2020 at: http://www.uniqure.com/gene-therapy/hemophilia.php
• 115 Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018; 16 (12) 2362-2374
• 116 Susen S, Gruel Y, Godier A. et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra^®): proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia 2019; 25 (05) 731-737
• 117 Collins PW, Liesner R, Makris M. et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018; 24 (03) 344-347
• 118 Ljung R, Auerswald G, Benson G. et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102 (02) 111-122
• 119 Young G. How I treat children with haemophilia and inhibitors. Br J Haematol 2019; 186 (03) 400-408
• 120 Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP. et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305 (13) 717-721
• 121 Hilgartner M, Aledort L, Andes A, Gill J. FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30 (07) 626-630
• 122 Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8 (02) 83-90
• 123 Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124 (04) 852-854
• 124 Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87 (05) 925-926
• 125 Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13 (03) 244-248
• 126 Eichler H, Angchaisuksiri P, Kavakli K. et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J ThrombHaemost 2018; 16 (11) 2184-2195
• 127 Chowdary P, Lethagen S, Friedrich U. et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13 (05) 743-754
• 128 Sehgal A, Barros S, Ivanciu L. et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (05) 492-497
• 129 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377 (09) 819-828
• 130 Gu JM, Zhao XY, Schwarz T. et al. Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys. AAPS J 2017; 19 (04) 1186-1195
• 131 Shirahata A, Fukutake K, Takamatsu J. et al. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics. Haemophilia 2013; 19 (06) 853-860
• 132 Ducore J, Lawrence JB, Simpson M. et al. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia 2017; 23 (06) 844-851
• 133 Spark Therapeutics. Pipeline. Published 2019. Accessed January 2, 2020 at: http://sparktx.com/scientific-platform-programs/